title: Absence of TGF-βRII predicts bone and lung metastasis and is associated with poor prognosis in stage III breast tumors.
abstract: In the case of operated breast cancer (BC), prognostic markers help to determine if the patient needs additional treatment and predictive markers help the clinician to decide which treatment to use. Thus, a better knowledge of known predictive and prognostic markers and the identification of new markers, may improve the treatment of BC patients. The transforming growth factor-beta type II receptor (TGF-βRII), a main receptor of transforming growth factor beta pathway, is a potential new prognostic marker. The aims of the present study were to investigate both the predictive and prognostic impact of TGF-βRII in BC samples. TGF-βRII protein expression was evaluated using immunohistochemistry on a tissue microarray containing 110 TNM stage III BC samples obtained prior to doxorubicin-based neoadjuvant chemotherapy (NAC). Our results demonstrate that TGF-βRII did not predict the response to NAC. On the other hand, an association between TGF-βRII-negative tumor and higher risk of metastasis to lungs and bones was verified. TGF-βRII negativity was an independent prognostic factor for decreased disease-free and overall survival.
authors.affiliation: Department of Clinical Oncology, Barretos Cancer Hospital, Barretos, São Paulo, Brazil. caredupai@gmail.com
authors.forename: Carlos Eduardo
authors.initials: CE
authors.lastname: Paiva
authors.forename: Sérgio Vicente
authors.initials: SV
authors.lastname: Serrano
authors.forename: Bianca Sakamoto Ribeiro
authors.initials: BS
authors.lastname: Paiva
authors.forename: Cristovam
authors.initials: C
authors.lastname: Scapulatempo-Neto
authors.forename: Fernando Augusto
authors.initials: FA
authors.lastname: Soares
authors.forename: Silvia Regina
authors.initials: SR
authors.lastname: Rogatto
authors.forename: Mariângela Esther Alencar
authors.initials: ME
authors.lastname: Marques
mesh_terms: D000328:Adult; D014408:Biomarkers, Tumor / Q000097:blood*; D001859:Bone Neoplasms / Q000556:secondary; D001943:Breast Neoplasms / Q000473:pathology* / Q000601:surgery; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D011379:Prognosis; D017346:Protein Serine-Threonine Kinases / Q000097:blood* / Q000235:genetics; D000077294:Receptor, Transforming Growth Factor-beta Type II; D018125:Receptors, Transforming Growth Factor beta / Q000097:blood* / Q000235:genetics
chemical_list: D014408:Biomarkers, Tumor; D018125:Receptors, Transforming Growth Factor beta; D017346:Protein Serine-Threonine Kinases; D000077294:Receptor, Transforming Growth Factor-beta Type II